
Revista Innovaci´on y Software
Vol. 6, No. 2, Mes Septiembre - Febrero, 2025
ISSN: 2708-0935
P´ag. 74-89
https://revistas.ulasalle.edu.pe/innosoft
Referencias
[1] S. Jabeen et al., “Disease specific symptoms indices in patients with celiac disease—a hardly recognised
entity,” Front Nutr, vol. 9, Sep 2022.
[2] B. Lebwohl and A. Rubio-Tapia, “Epidemiology, presentation, and diagnosis of celiac disease,” Gastroen-
terology, vol. 160, no. 1, pp. 63–75, Jan 2021.
[3] A. F. Syam et al., “Prevalence and factors associated with celiac disease in high-risk patients with fun-
ctional gastrointestinal disorders,” PLoS One, vol. 19, no. 6, p. e0297605, Jun 2024.
[4] ¨
O. Aydemir et al., “Polymorphisms in intron 1 of hla-dra differentially associate with type 1 diabetes and
celiac disease,” Jun 2023.
[5] E. Crehu´a-Gaudiza et al., “Diagn´ostico de enfermedad celiaca en la pr´actica cl´ınica: presente y futuro,”
An Pediatr (Engl Ed), vol. 94, no. 4, pp. 223–229, Apr 2021.
[6] T. B. Houmich and B. Admou, “Celiac disease: Understandings in diagnostic, nutritional, and medicinal
aspects,” Int J Immunopathol Pharmacol, vol. 35, Jan 2021.
[7] P. Singh et al., “Who to screen and how to screen for celiac disease,” World J Gastroenterol, vol. 28,
no. 32, pp. 4493–4507, Aug 2022.
[8] A. H. Abend et al., “Estimation of prevalence of autoimmune diseases in the united states,” J Clin Invest,
vol. 135, no. 4, Dec 2024.
[9] D. Andari et al., “Clinical presentations and outcomes of celiac disease in children and adolescents,” Front
Pediatr, vol. 13, Jan 2025.
[10] C. M. Trovato et al., “Clinical presentations of celiac disease,” Nutrients, vol. 17, no. 1, p. 129, Dec 2024.
[11] A. A. Esmail et al., “Celiac disease among outpatient attendees with gastrointestinal complaints,”
USTJMS, vol. 3, Feb 2025.
[12] H. Wieser et al., “Gastrointestinal and hepatobiliary manifestations associated with untreated celiac
disease,” J Clin Med, vol. 13, no. 15, p. 4579, Aug 2024.
[13] M. Alfawaz et al., “Clinical characteristics of celiac disease patients in qassim region,” J Family Med Prim
Care, vol. 13, no. 3, pp. 827–832, Mar 2024.
[14] G. Ortiz et al., “New cut-off values of antitransglutaminase antibodies processed by chemiluminescence,”
JPGN Rep, vol. 6, no. 2, pp. 107–112, May 2025.
Facultad de Ingenier´ıa
Universidad La Salle, Arequipa, Per´u
facin.innosoft@ulasalle.edu.pe
88